


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技（武漢）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

VOLUNTARY ANNOUNCEMENT
ANNOUNCEMENT REGARDING COLLABORATION
BETWEEN HANX BIOPHARMACEUTICALS AND
HUST ADVANCED INTERDISCIPLINARY RESEARCH
CENTRE ON AI-DRIVEN DRUG DISCOVERY

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the “**Company**” or “**Hanx Biopharmaceuticals**”) on a voluntary basis.

OVERVIEW OF THE COLLABORATION

To fully leverage the strengths of industry-university-research integration and accelerate innovation in biomedical research and development, Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (hereinafter referred to as the “**Company**” or “**Hanx Biopharmaceuticals**”) has recently formally entered into the Cooperation Agreement for the Joint Establishment of the Joint Laboratory for Artificial Intelligence-Driven Drug Discovery (《「人工智能藥物研發聯合實驗室」合作共建協議》) with the Advanced Interdisciplinary Research Centre of the HUST-CityU Macau Institute of Advanced Studies.

Drawing on the AI platform of the Advanced Interdisciplinary Research Centre of HUST, as well as Hanx Biopharmaceuticals’ extensive experience in innovative drug R&D and in-depth understanding of disease areas, both parties will carry out in-depth collaboration focusing on antibody discovery and molecular design, and jointly establish a new-generation paradigm for AI-driven innovative drug development.

ABOUT HANX BIOPHARMACEUTICALS

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was founded in 2014 as an innovative biotechnology enterprise focusing on structural biology, translational medicine and clinical development. The Company is dedicated to developing next-generation immunotherapies to deliver affordable, safe and effective medical solutions for patients worldwide to address challenges posed by major diseases. Upholding its innovation-driven mission and vision, Hanx Biopharmaceuticals concentrates on the discovery, research and development, and commercialisation of precision therapeutic products for cancers and autoimmune diseases. The Company strives to satisfy unmet global medical needs, facilitate the prevention, management and mitigation of diseases, and contribute to the advancement of global healthcare.

ABOUT THE ADVANCED INTERDISCIPLINARY RESEARCH CENTRE OF HUST-CITYU MACAU INSTITUTE OF ADVANCED STUDIES

The Centre was jointly established by Huazhong University of Science and Technology, a national key university, and the Institute of Advanced Studies of City University of Macau. Focusing on cutting-edge interdisciplinary subjects, the Centre integrates advanced material design, high-performance computing and state-of-the-art AI algorithms. It boasts world-leading research capabilities in macromolecular dynamics simulation, bioinformatics computation and cross-disciplinary applications of multi-physics fields.

SCOPE OF COLLABORATION

The collaboration mainly covers the following two major areas:

1. **AI-Assisted Antibody Optimisation:** Leveraging the multi-scale molecular dynamics simulation and deep learning models owned by the Advanced Interdisciplinary Research Centre, both parties will conduct digital screening of large-scale antibody libraries and prediction of affinity maturation. This will significantly shorten the antibody discovery cycle, enhance the target specificity and binding efficiency of candidate antibodies, and reduce the trial-and-error costs incurred by conventional wet-lab experiments.
2. **Intelligent Molecular Design and Development:** Both parties shall jointly develop and deploy advanced generative AI models for “De Novo Design” of cutting-edge molecules. Through intelligent prediction and multi-objective optimisation of molecular structures, physicochemical properties as well as ADME (absorption, distribution, metabolism, excretion and toxicity) profiles, the collaboration will accelerate the identification of drug candidate molecules with the highest potential.

This collaboration will optimise the Company's antibody screening and molecular optimisation workflows, elevate research and development efficiency and success rates, substantially shorten R&D cycles and cut research and development costs, as well as accelerate the Company's progress in FIC and BIC drug discovery. Relevant research outputs will further enrich the Company's R&D pipeline, consolidate its technological edges and core competitiveness, and provide robust support for the Company's long-term development and sustainable operations.

Warning Statement pursuant to Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no guarantee that the relevant products will eventually be successfully developed and launched for sale. Shareholders and potential investors of the Company shall exercise caution when trading the Company's shares.

By order of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, July 7, 2026

As at the date of this announcement, the Company's Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li, Ms. Xiao Jieyu and Mr. Liu Min as executive Directors; (ii) Dr. Li Jian as a non-executive Director; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.